12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pralia denosumab regulatory update

Daiichi Sankyo said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Pralia denosumab to treat osteoporosis. The human mAb targeting receptor activator of NF-kappa B ligand ( RANKL) is approved in Japan as Ranmark to treat bone complications stemming from multiple...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >